112
Participants
Start Date
August 15, 2025
Primary Completion Date
December 30, 2026
Study Completion Date
June 30, 2029
Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab
"Patients who meet the inclusion criteria will be enrolled and given paclitaxel oral solution and subcutaneous pertuzumab/trastuzumab for neoadjuvant treatment.~Paclitaxel oral solution: 200mg/m2 po bid, D1,D8,D15, q3w. Subcutaneous pertuzumab/trastuzumab: 1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL, q3w."
NOT_YET_RECRUITING
Peking University Cancer Hospital, Beijing
NOT_YET_RECRUITING
Guangdong Women and children Hospital, Guangzhou
RECRUITING
Sun Yat-sen Memorial Hospital, Guangzhou
NOT_YET_RECRUITING
Cancer Hospital of Shantou University Medical College, Shantou
NOT_YET_RECRUITING
Guangxi Provincial Cancer Hospital, Nanning
NOT_YET_RECRUITING
The Affiliated Hospital of Guizhou Medical University, Guiyang
NOT_YET_RECRUITING
Hainan Central Hospital, Haikou
NOT_YET_RECRUITING
the First Affiliated Hospital of Wenzhou Medical University, Wenzhou
NOT_YET_RECRUITING
Peking University Shenzhen Hospita, Shenzhen
Peking University Cancer Hospital & Institute
OTHER
Peking University Shenzhen Hospital
OTHER
Hainan People's Hospital
OTHER
The Affiliated Hospital Of Guizhou Medical University
OTHER
Nanfang Hospital, Southern Medical University
OTHER
Guangdong Women and Children Hospital
OTHER
Affiliated Cancer Hospital of Shantou University Medical College
OTHER
First Affiliated Hospital of Wenzhou Medical University
OTHER
Cancer Hospital of Guangxi Medical University
OTHER
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
OTHER